Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

Ora, Inc.

Status and phase

Completed

Phase 2

Conditions

Dry Eye Disease

Treatments

Drug: Placebo Ophthalmic Solution

Drug: PL9643 Ophthalmic Solution

Study type

Interventional

Funder types

Industry

Identifiers

NCT04268069

PL9643-201

Details and patient eligibility

About

Evaluation of safety and efficacy of PL9643 Ophthalmic Solution compared to placebo for the treatment of the signs and symptoms of dry eye.

Full description

The clinical trial is a Phase 2, multi center, randomized, double masked and placebo controlled study.

During a 14-day study run-in period (for the purpose of subject selection) prior to randomization, all subjects will receive Placebo Ophthalmic Solution (vehicle) bilaterally. During the screening period, exposure to the CAE® will be conducted to ascertain eligibility to enter the study at Visit 1 and Visit 2. Those who qualify at Visit 2 will be randomized to receive study drug in a double-masked fashion for 12 weeks. The CAE® exposure will occur at all Visits.

Enrollment

160 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Be at least 18 years of age.
Provided written informed consent.
Have a reported history of dry eye
Have a history of use or desire to use eye drops for dry eye symptoms
Have corrected visual acuity greater than or equal to +0.7 in both eyes

Exclusion criteria

Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal)
Have any planned ocular and/or lid surgeries over the study period.
Have an uncontrolled systemic disease.
Be a woman who is pregnant, nursing or planning a pregnancy.
Be a woman of childbearing potential who is not using an acceptable means of birth control
Have a known allergy and/or sensitivity to the test article or its components.
Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
Have used an investigational drug or device within 30 days of Visit 1
Be unable or unwilling to follow instructions, including participation in all study assessments and visits